Recently, the State Drug Administration approved the listing registration application of bevacizumab injection (trade name: anda) developed by Qilu Pharmaceutical Co., Ltd.
The drug is the first bevacizumab biological analogue approved in China. It is mainly used for the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer. The approval and marketing of this product will improve the accessibility of this kind of drugs and provide a new choice for the treatment of domestic patients.